Company intelligence / Profile preview

Genomill Health

Turku, Southwest Finland, Finland

Ownership: Private
Development stage: Other

Overview

Genomill Health is a Finnish precision diagnostics company specializing in innovative, cost-efficient, and ultra-sensitive NGS-based genetic testing, primarily leveraging its proprietary Geno1 platform for liquid biopsy applications in cancer. Their tests are platform-agnostic, rapid, and aim to make molecular diagnostics more accessible. The company is collaborating with Finnish Cancer Research Flagship iCAN for cancer detection initiatives using large biobank cohorts.

Therapeutic areas: Oncology
Modalities: Genomic sequencing-based diagnostics
Industry: Molecular Diagnostics

Partnerships

iCAN (Finnish Cancer Research Flagship)

Beyond the preview

Go deeper on Genomill Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomill Health.

Explore the full profile